

1 ELLIS GEORGE LLP
Matthew L. Venezia (State Bar No. 313812)
2 mvenezia@ellisgeorge.com
George B. A. Laiolo (State Bar No. 329850)
3 glaiolo@ellisgeorge.com
2121 Avenue of the Stars, 30th Floor
4 Los Angeles, California 90067
Telephone: (310) 274-7100
5 Facsimile: (310) 275-5697

6 Attorneys for Plaintiff
ANTHONY RANDALL
7

8 UNITED STATES DISTRICT COURT
9 CENTRAL DISTRICT OF CALIFORNIA
10 WESTERN DIVISION

11 ANTHONY RANDALL,

12 Plaintiff,

13 vs.

14 UNITED NETWORK FOR ORGAN
SHARING; CEDARS-SINAI
15 MEDICAL CENTER,

16 Defendants.
17
18
19
20
21
22
23
24
25
26
27
28

Case No. 2:23-CV-02576-MEMF (MAAx)

**SECOND AMENDED COMPLAINT
FOR:**

**(1) VIOLATION OF TITLE VI OF
THE CIVIL RIGHTS ACT OF 1964;**

**(2) VIOLATION OF THE UNRUH
CIVIL RIGHTS ACT [CALIFORNIA
CIVIL CODE § 51];**

**(3) BREACH OF FIDUCIARY DUTY;
AND**

**(4) VIOLATION OF CALIFORNIA'S
UNFAIR COMPETITION LAW [CAL.
BUS. & PROF. CODE § 17200 ET
SEQ.]**

Action Filed: April 5, 2023

1 Plaintiff Anthony Randall (“Plaintiff”) brings this Complaint individually, and
2 on behalf of all persons similarly situated, against the United Network for Organ
3 Sharing and Cedars-Sinai Medical Center (“Defendants”), and alleges as follows:

4 **INTRODUCTION**

5 1. Black Americans are more than three times as likely to suffer from
6 kidney failure when compared to White Americans. As a group, and as a result of
7 ongoing racial inequality, Black Americans are at higher risk for maladies such as
8 high blood pressure, obesity, diabetes, and heart disease, each of which increase the
9 likelihood of suffering kidney disease.

10 2. Despite being overrepresented when it comes to kidney disease, and
11 overrepresented on the national waitlist for donor kidneys, Black Americans are much
12 less likely than their White counterparts to actually receive a kidney transplant.

13 3. Kidney function is measured by an estimated glomerular filtration rate
14 test, commonly referred to as eGFR. A patient’s eGFR score is used to determine
15 when the patient is eligible to begin accruing wait time on the national kidney waitlist,
16 with the score needing to fall below 20 ml/min to qualify a patient to begin accruing
17 wait time.

18 4. When current tests for the eGFR were developed, a few flawed studies
19 indicated Black Americans had higher creatinine extraction rates, and instead of
20 considering whether this difference could be caused by non-racial societal factors, it
21 was postulated by the developers of the eGFR that Black Americans’ scores could be
22 explained because Black Americans have more muscle mass and thus more creatinine
23 in their systems than White Americans.

24 5. Based on this postulation, the creators of the eGFR added a race-based
25 modifier to eGFR scores, known as the “race-based coefficient,” which artificially
26 inflates the scores of Black Americans by 16–18%. That is, eGFR is calculated
27 irrespective of race, and then only for Black patients, the score is increased by 16–
28 18%, based upon the flawed premise that Black Americans have greater muscle mass

1 and thus naturally have more creatinine in their bodies.

2 6. This, of course, is junk science supported only by racial stereotypes, and
 3 not any valid scientific studies. As described in an article titled *Systemic Kidney*
 4 *Transplant Inequities for Black Individuals: Examining the Contribution of*
 5 *Racialized Kidney Function Estimating Equations*, the theory supporting the race-
 6 based modification to Black patients' eGFR scores has "not been substantiated by
 7 rigorous scientific evidence[.]"

8 7. Indeed, the United Network for Organ Sharing ("UNOS") recently
 9 admitted as much, posting the following passage on its website:



Organ donors

Patients

What are other issues with the race variable in eGFR?

EGFR calculations rely on a binary approach to race. When the race variable is used in formulas, eGFR calculators only offer two response options: "Black" or "Not Black."

These options do not include a designation for mixed race or multi-racial individuals, and do not account for the existing genetic diversity within the Black population. The concept of race is a social construct and an unreliable proxy for genetic difference, therefore not a biological marker or clinical measure.

10
11
12
13
14
15
16
17
18
19
20 8. This is important because eGFR scores are used to determine when a
 21 patient is eligible to begin accruing wait time on the national kidney waitlist,
 22 maintained by UNOS, and wait time is a key factor in determining which patient will
 23 be awarded a kidney, as kidneys become available. Again, for an eGFR score to
 24 qualify a patient with kidney disease to accrue wait time, the eGFR score must fall
 25 below 20 ml/min.

26 9. However, until recently, application of the race-based coefficient
 27 artificially increased Black patients' eGFR scores above that threshold such that Black
 28 patients' unmodified eGFR scores must have fallen well below 20 ml/min before they

1 began accruing wait time.

2 10. Indeed, because of the race-based coefficient, many Black patients never
3 began to accrue wait time because of a qualifying eGFR score, but were instead
4 delayed until such time as they were forced to begin dialysis, the other possible
5 triggering factor for wait time, which is recommended when kidney function falls
6 below 15 ml/min, or when certain symptoms of kidney disease present themselves.

7 11. It is true that UNOS recently announced it was outlawing use of the race-
8 based coefficient when measuring eGFR scores. UNOS's announcements rightly
9 admit the discriminatory nature of their past policy, but will also prove too little too
10 late for many Black Americans currently suffering kidney failure.

11 12. In this regard, UNOS announced its intent to change course and outlaw
12 use of the race-based coefficient in June of 2022, but did nothing for more than six
13 months to address the erroneous wait time calculations for Black Americans already
14 on the national kidney waitlist.

15 13. In January of 2023, UNOS did instruct donor hospitals to notify Black
16 candidates of the policy change and investigate whether Black members of their donor
17 lists were eligible for a wait time modification, but UNOS gave donor hospitals a year
18 to complete this process, until January of 2024.

19 14. Indeed, Cedars-Sinai, the donor hospital for Plaintiff and 205 other Black
20 Americans suffering from kidney disease, took no steps whatsoever to address
21 erroneous wait time calculations, until March 27, 2023, when it advised members of
22 its waitlist that the issue would be considered over "[o]ver the next several months[.]"

23 15. Unfortunately, in the time between June of 2022 and January of 2024,
24 tens of thousands of Black Americans will be prejudiced in their candidacy for a donor
25 kidney by use of erroneous wait time calculations, missing out on donor kidneys they
26 rightfully should have been awarded, incurring significant economic losses, suffering
27 from worsened kidney disease, and in some instances, dying.

28 16. In other words, many Black Americans suffering from kidney disease

1 did not have 18 months for UNOS to fix its wait time calculations, and during this
2 period, Black Americans continue to suffer racial discrimination in the kidney
3 donation process, despite all involved admitting that the current process is
4 discriminatory to Black Americans.

5 17. Plaintiff Anthony Randall is one such Black American that was on
6 UNOS's national kidney transplant waitlist. Plaintiff, having suffered previous
7 symptoms of kidney failure, took monthly eGFR tests for years, until such time as his
8 eGFR score, despite continued application of the race-based coefficient, was low
9 enough for him to begin accruing wait time on the national kidney waitlist.

10 18. Plaintiff was on the national kidney transplant waitlist for more than five
11 years, but upon information and belief, should have qualified to accrue wait time years
12 earlier absent application of the race-based coefficient. As recently as December of
13 2022, Plaintiff was advised he "finished second" for a kidney, but upon information
14 and belief, had Plaintiff's wait time been properly calculated, without regard to his
15 race, Plaintiff would have received a transplant kidney in December of 2022, or
16 earlier.

17 19. New donor kidneys become available on a daily basis, and as the health
18 of Black patients on the waitlist deteriorates, the failure to properly calculate Black
19 patients' wait time such that they can be fairly considered for kidneys as they become
20 available jeopardize their lives. This is true for the other 205 Black patients at Cedars-
21 Sinai, and approximately 27,500 Black members of the national kidney waitlist.

22 **PARTIES**

23 20. Plaintiff Anthony Randall is an individual residing in Los Angeles,
24 California.

25 21. Plaintiff is informed and believes, and thereon alleges, that Defendant
26 UNOS is a Virginia nonprofit corporation with its principal place of business in
27 Richmond, Virginia.

28 22. Plaintiff is informed and believes, and thereon alleges, that Defendant

1 Cedars-Sinai Medical Center (“Cedars-Sinai”) is a California nonprofit corporation
 2 with its principal place of business in Los Angeles, California.

3 **JURISDICTION AND VENUE**

4 23. This Court has federal question jurisdiction over this matter pursuant to
 5 28 U.S.C. §§ 1331, 1332(d), and 1343 because Plaintiff asserts a federal cause of
 6 action alleging racial discrimination, and because at least one member of the putative
 7 classes defined hereinafter is a citizen of a different state than all Defendants, and the
 8 amount in controversy exceeds \$5,000,000. This Court further has supplemental
 9 jurisdiction over any state law claims pursuant to 28 U.S.C. § 1367.

10 24. Venue in this district is proper pursuant to 28 U.S.C. § 1391 because
 11 Plaintiff resides in this District and has been affected by Defendants’ unlawful
 12 policies and procedures within the District, Cedars-Sinai’s principal place of business
 13 is within this District, and Cedars-Sinai’s alleged actions have occurred within the
 14 District. Defendants also apply their unlawful policies and procedures to additional
 15 putative class members residing within the District. Thus, a substantial part of the
 16 events or omissions that gave rise to the claims asserted herein occurred within this
 17 District.

18 25. This Court has personal jurisdiction over UNOS because UNOS
 19 conducts operations within California by virtue of its management of the kidney donor
 20 list for all patients residing within the State, including Plaintiff. UNOS makes
 21 decisions as to which patients residing in California will be offered donor kidneys.

22 26. This Court has personal jurisdiction over Cedars-Sinai because Cedars-
 23 Sinai maintains its principal place of business within the State, and harmed Plaintiff
 24 by virtue of the unlawful conduct alleged herein within this State.

25 **GENERAL ALLEGATIONS**

26 **A. The national kidney transplant waitlist is controlled by the** 27 **Defendants, and wait time is the primary factor considered in** 28

1 **awarding donor kidneys.**

2 27. In 1984, Congress passed the National Organ Transplant Act, creating
3 the Organ Procurement and Transplantation Network (“OPTN”), which was tasked
4 with maintaining a national registry for organ matching. Per the Act, this registry was
5 to be operated by a private, non-profit organization under Federal contract.¹

6 28. Since that time, UNOS has acted as that private, non-profit organization,
7 and per its website, UNOS “[m]anag[es] the national transplant waiting list, matching
8 donors to recipients 24 hours a day, 365 days a year.” UNOS establishes and
9 implements policy concerning how donor kidneys will be awarded to patients with
10 kidney disease.

11 29. To be placed on the national kidney transplant waitlist, a patient must
12 first visit one of 200+ transplant hospitals, and receive a referral from their physician.
13 In this way, the transplant hospitals, like Cedars-Sinai, serve as a gatekeeper to
14 patients seeking to be placed on the national kidney waitlist.

15 30. The national kidney transplant waitlist is maintained using UNOS
16 software, known as UNet. When a new patient is added to the waitlist, the referring
17 hospital enters the patient’s name and relevant medical information, including eGFR
18 scores, into the UNet software, which tracks patient medical information and wait
19 time.

20 31. Each time a donor kidney becomes available, UNet’s algorithm
21 considers the information maintained in UNet, and generates a list of potential
22 matches, ranking potential matches on the national kidney waiting list. These kidneys
23 are then offered to patients through the transplant hospitals, in accordance with the
24 UNet-generated rankings.

25 32. Upon information and belief, the primary factor considered by UNet’s
26 algorithm to rank candidates for potentially compatible kidneys is a patient’s accrued
27

28 ¹ Patients can also seek a kidney from a private donor, such as a family member or friend, at the same time as they wait for a kidney on the national waitlist.

1 wait time. In other words, UNet will identify patients that are a medical match for a
2 particular available kidney, and then rank those patients according to wait time.

3 33. Importantly, referral to the waitlist does not automatically start the clock
4 on qualifying wait time. To accrue qualifying wait time, generally a patient's eGFR
5 score must either fall below 20 ml/min, or the patient must begin dialysis.

6 **B. The Defendants applied a racially discriminatory coefficient to**
7 **eGFR scores for Black patients.**

8 34. Again, UNOS is responsible for enacting policy concerning the selection
9 of which patients receive which donor kidneys. In this regard, UNOS offers as one of
10 its strategic goals to "[p]rovide equity in access to transplants[.]" UNOS has fallen far
11 short of its stated goal.

12 35. For decades, the race-based coefficient was applied to artificially inflate
13 eGFR scores for Black Americans, overstating their kidney function by 16–18%,
14 based upon the underlying assumption that Black Americans have greater muscle
15 mass and thus naturally have more creatinine in their system.

16 36. As noted above, patients do not begin accruing wait time on the national
17 kidney waitlist until their eGFR score reaches 20 ml/min. But for Black patients, even
18 when their unadjusted eGFR score fell below 20 ml/min, the race-based coefficient
19 was applied to artificially inflate the Black patients' eGFR scores above 20 ml/min,
20 preventing them from qualifying to accrue wait time. Thus, Black patients' eGFR
21 scores had to fall well below 20 ml/min before they began to accrue wait time.

22 37. UNOS policy encouraged and allowed for use of the race-based
23 coefficient, and UNOS knowingly used modified eGFR scores and manipulated wait
24 times when ranking patients for kidney transplants. Specifically, UNOS is and has at
25 all times been aware that its UNet software includes an algorithm that uses wait time
26 as the primary factor in ranking patients for donor kidneys, and that its UNet software
27 includes wait times for Black patients that have been manipulated by use of the race-
28 based coefficient. To be clear, this modification was made to Black patients' eGFR

1 scores entirely because of their race, and was not applied to other racial groups.

2 38. There has never been any serious scientific research to support use of the
3 race-based coefficient to artificially increase Black patients' eGFR scores. Instead,
4 the race-based coefficient is based on eugenics-style racism and stereotypes that
5 assume Black Americans are more physically fit than White Americans and other
6 racial groups.

7 39. Years before UNOS took any action to review its policy allowing for use
8 of the race-based coefficient, the practice was criticized by doctors for its racially
9 discriminatory nature. For example, in November of 2011, Dr. Toni Martin published
10 an article in the *American Journal of Kidney Diseases* that questioned the practice,
11 explaining that when she attempts to explain the policy to Black patients, she "get[s]
12 a snort of disbelief[,]” and noting the history of purported genetic differences being
13 used against Black Americans against a backdrop of “separate and unequal.”

14 40. Use of the race-based coefficient seriously diminishes Black patients'
15 chances to receive a donor kidney, and for Black patients that defeat the odds and
16 ultimately receive a kidney from the national waitlist, their waiting time is still
17 increased. Indeed, because of this eGFR manipulation, many Black patients never
18 qualified to accrue wait time because of their eGFR score, and only began to accrue
19 wait time when they began dialysis.

20 41. All other factors being equal, the above-described practices have resulted
21 in non-Black patients receiving numerous kidneys that would otherwise have been
22 given to Black applicants had their wait time been calculated without consideration
23 of race.

24 42. The failure to receive donor kidneys has caused significant harm to Black
25 Americans. The unfortunate reality is that many Black Americans have already passed
26 away that would have survived if given fair consideration for a donor kidney.

27 43. Other Black Americans have suffered worsened kidney disease and/or
28 been forced to go on dialysis because of the lengthened wait time for a donor kidney.

1 These Black Americans have suffered economic damages in the form of medical
2 expenses and lost wages.

3 **C. Even after UNOS admitted the race-based coefficient discriminates**
4 **against Black Americans, Defendants failed to timely address the**
5 **problem.**

6 44. In June of 2022, UNOS admitted the racially discriminatory nature of
7 the race-based coefficient for Black Americans, approving “a measure to require
8 transplant hospitals to use a race-neutral calculation when estimating a patient’s level
9 of kidney function.” In its press release, UNOS explained that

10 For a number of years, some eGFR calculations have
11 included a modifier for patients identified as Black. This
12 practice has led to a systemic underestimation of kidney
13 disease severity for many Black patients. Specifically in
organ transplantation, it may have negatively affected the
timing of transplant listing or the date at which candidates
qualify to begin waiting time for a transplant.²

14 45. UNOS policy officially changed on July 27, 2022, with UNOS policy
15 prior to that time expressly allowing for use of the race-based coefficient to artificially
16 increase Black patients’ eGFR scores.

17 46. Nonetheless, UNOS continued to use the race-based coefficient as a
18 default. For more than six months, UNOS took no affirmative steps to adjust wait
19 times and correct for previous use of the race-based coefficient.

20 47. On January 5, 2023, UNOS announced a new policy that would require
21 donor hospitals to provide two notifications to patients on the national kidney waitlist,
22 one notifying patients that Black Americans will be considered for wait time
23 adjustments where the race-based coefficient delayed their accrual of wait item, and
24 a second notification confirming this process was completed and informing patients
25 of their status. UNOS also directed donor hospitals to investigate which patients are
26 eligible for a wait time adjustment, and request said adjustments within a year, i.e.,
27

28 ² This Press release is publicly available at <https://unos.org/news/optn-board-approves-elimination-of-race-based-calculation-for-transplant-candidate-listing/>.

1 by January of 2024.

2 48. While this adjustment in policy rightfully acknowledges the problem, it
3 lacked required urgency, and for the 27,500 Black Americans on the national kidney
4 waitlist, such as Plaintiff, the policy change is too little too late. UNOS's policy
5 concerning the race-based coefficient to eGFR scores was racially discriminatory
6 before UNOS ever acknowledged the problem, and instead of making immediate
7 changes, UNOS allowed member transplant hospitals approximately 18 months to
8 identify and attempt to correct falsely-calculated wait times.

9 49. During this period, Black Americans continued to suffer a race-based
10 disadvantage in their candidacy for a donor kidney—UNet continuing to utilize the
11 old, improperly calculated wait times when awarding kidneys.

12 50. UNOS ultimately failed to process wait-time adjustments as promised.
13 As of January 15, 2024, UNOS had completed only 14,849 wait-time adjustments
14 where there are approximately 27,500 Black Americans currently on the waitlist.

15 **D. Plaintiff has been discriminated against by the race-based**
16 **coefficient to eGFR scores for years, and has never been awarded a**
17 **kidney.**

18 51. Plaintiff first discovered that he suffered from kidney disease
19 approximately 24 years ago when he became ill and passed out, while in San Diego,
20 California. For many years thereafter, Plaintiff's kidney disease was managed with
21 medications.

22 52. However, having been diagnosed with kidney disease, Plaintiff
23 underwent monthly testing of his eGFR to determine his kidney function. Upon
24 information and belief, at all times the race-based coefficient was used to artificially
25 inflate Plaintiff's eGFR scores.

26 53. Plaintiff's artificially inflated eGFR scores first qualified Plaintiff to
27 begin accruing wait time on the national kidney waitlist in January of 2018. Plaintiff
28 has remained on the waitlist since that time, now having been on the list for more than

1 five years, but has never been awarded a donor kidney.

2 54. Upon information and belief, Plaintiff's non-modified eGFR score fell
3 below 20 ml/min, as is required to begin to accrue wait time, well before January of
4 2018.

5 55. Accordingly, but for use of the race-based coefficient, Plaintiff would
6 have begun to accrue wait time prior to January of 2018, entitling Plaintiff to an earlier
7 spot in line that would have increased Plaintiff's chances to receive a donor kidney.

8 56. Upon information and belief, but for the application of the race-based
9 coefficient to Plaintiff's eGFR score, Plaintiff would have received a donor kidney
10 from the national waitlist significantly earlier than his actual transplant, instead of
11 having to rely on a private donor.

12 57. In this regard, in December of 2022, Plaintiff received a call from
13 Cedars-Sinai telling him to rush to Cedars-Sinai because a donor kidney was located.
14 Plaintiff was held at the hospital for 17 hours, prepped for surgery, including not
15 eating or drinking, only to be told that the donor kidney had been awarded to and
16 implanted into another patient. Cedars-Sinai only then explained that Plaintiff had
17 been requested to rush to the hospital as an alternate, and that the kidney had been
18 given to the first choice.

19 58. However, at this time, Plaintiff's accrued wait time had not been
20 recalculated to account for the delay caused by use of the race-based coefficient.
21 Despite UNOS's clear admission in June of 2022 that the race-based coefficient is
22 racially discriminatory towards Black Americans, neither UNOS nor Cedars-Sinai
23 had taken any steps by December of 2022 to recalculate Plaintiff's wait time
24 calculation.

25 59. Upon information and belief, but for the racially discriminatory formula
26 used to determine who would be awarded this particular kidney, resulting in an
27 improper calculation of Plaintiff's wait time, Plaintiff would have been awarded and
28 received a donor kidney in December of 2022, at the latest.

1 60. Indeed, Cedars-Sinai took no action whatsoever in response to UNOS's
2 recent policy change until March 27, 2023, when Cedars-Sinai sent notice that it
3 would begin reviewing members of its kidney wait list to determine whether wait time
4 adjustments were required "[o]ver the next several months[.]"

5 61. Because this first notice was required to be "sent before the program's
6 assessment of their list," and given the wording of the notice, it is clear that even after
7 UNOS announced the race-based coefficient may no longer be used, Cedars-Sinai sat
8 on its hands and did not even begin the process to evaluate whether any of the
9 members of its waitlist were entitled to a wait time adjustment for another nine
10 months.

11 **E. As a result of not being awarded a kidney in the transplant market,**
12 **Plaintiff has suffered significant economic harms.**

13 62. Over the past years, Plaintiff's kidney disease has worsened
14 significantly. In January of 2022, Plaintiff's condition worsened to the point that he
15 became unable to work, and since that time, Plaintiff has been unable to return to
16 work. This has caused Plaintiff significant economic harm in the form of lost wages
17 and medical expenses, particularly ongoing dialysis costs.

18 **CLASS ACTION ALLEGATIONS**

19 63. Plaintiff brings this action on behalf of himself and the below-defined
20 putative classes who are similarly situated under Rules 23(a), (b)(2), and (b)(3) of the
21 Federal Rules of Civil Procedure.

22 64. The National Waitlist Class seeks damages and is defined as follows:

- 23 • All patients identified as Black on the national kidney waitlist, for whom
24 the accrual of wait time was delayed by application of the race-based
25 coefficient. This class excludes those patients pursuing personal injury
or wrongful death claims.

26 65. Additionally, Plaintiff brings this action on behalf of the subclasses
27 defined below.

28 66. The California Waitlist Class seeks damages and is defined as follows:

- All patients identified as Black on the national kidney waitlist, residing in California, for whom the accrual of wait time was delayed by application of the race-based coefficient. This class excludes those patients pursuing personal injury or wrongful death claims.

67. The Cedars-Sinai Waitlist Class seeks damages and is defined as follows:

- All patients identified as Black on the national kidney waitlist, for whom Cedars-Sinai was their designated transplant hospital, and for whom the accrual of wait time was delayed by application of the race-based coefficient. This class excludes those patients pursuing personal injury or wrongful death claims.

68. Upon information and belief, given that the national kidney waitlist includes approximately 27,500 Black Americans nationwide, the National Waitlist Class includes tens of thousands of members located throughout the United States.

69. Upon information and belief, given that there are more than 2,000 Black members of the national kidney waitlist residing in California, the California Waitlist Class includes thousands of members located in California.

70. Upon information and belief, and because Cedars-Sinai represents that 206 of its patients are potentially eligible for wait time adjustments, the Cedars-Sinai Class includes hundreds of members located in California.

71. The identities of the members of the National Waitlist Class, California Waitlist Class, and Cedars-Sinai Class are known or readily ascertainable by UNOS and Cedars-Sinai, and the number of persons who fall within the definition of these classes are so numerous and geographically dispersed as to make joinder of all members of the National Waitlist Class, California Waitlist Class, or Cedars-Sinai Class in their individual capacity impracticable, inefficient, and unmanageable so as to effectively deny each putative member of these classes his, her, or their right to obtain relief based on the claims and allegations made in this Complaint.

72. There are common questions of law and fact as to the National Waitlist Class, California Waitlist Class, and Cedars-Sinai Class, relating to and/or dispositive of the allegations of unlawful and misleading conduct made in the Complaint, and

1 relating to and/or dispositive of the common pattern of alleged injury and harm caused
 2 by that unlawful and misleading conduct and sustained by the putative members of
 3 the classes, including, but not limited to:

- 4 • Whether UNOS discriminated against members of the classes on account
 5 of their race by encouraging and allowing for use of the race-based
 coefficient;
- 6 • Whether UNOS discriminated against members of the classes on account
 7 of their race by its knowing use of manipulated wait time data in the
 UNet algorithm;
- 8 • Whether UNOS's UNet algorithm was racially biased and led to delay
 9 for Black candidates seeking donor kidneys;
- 10 • Whether the disparate impact of UNOS's policy allowing for use of the
 11 race-based coefficient and the UNet algorithm was known to UNOS
 during the relevant time period, leading to the uniform disparate
 treatment of members of the classes;
- 12 • UNOS's knowledge of their practices and the discriminatory impact on
 13 the classes;
- 14 • Whether Cedars-Sinai discriminated against members of the Cedars-
 15 Sinai classes on account of their race by encouraging and allowing for
 use of the race-based coefficient;
- 16 • Whether Cedars-Sinai discriminated against members of the Cedars-
 17 Sinai Class on account of their race by its failure to provide accurate wait
 18 time data for inclusion in UNet;
- 19 • Whether Cedars-Sinai's failure to provide accurate wait time data for
 20 inclusion in UNet was racially biased and led to delay for Black
 21 candidates seeking donor kidneys;
- 22 • Whether the disparate impact of Cedars-Sinai's failure to provide
 23 accurate wait time date for inclusion in UNet was known to Cedars-Sinai
 24 during the relevant time period, leading to the uniform disparate
 25 treatment of the Cedars-Sinai Class;
- 26 • Cedars-Sinai's knowledge of their practices and the discriminatory
 impact on the Cedars-Sinai Class;
- 27 • Whether Cedars-Sinai owes its patients on the kidney waitlist a fiduciary
 28 duty, and whether Cedars-Sinai's failure to provide accurate wait time
 information for use in UNet violated such a duty; and
- The length of the delay caused by use of the race-based coefficient and
 increased medical costs resulting therefrom.

73. The interests of Plaintiff and the classes are aligned. Plaintiff seeks to

1 establish that UNOS and Cedars-Sinai are liable for economic injuries caused to Black
2 patients by application the race-based coefficient. Should Plaintiff prevail in
3 establishing the same, each of the other members of the classes would then be entitled
4 to recover damages in compensation for their economic injuries.

5 74. The claims of Plaintiff are typical of the claims of the members of the
6 class and subclasses. Plaintiff is a Black member of the national kidney waitlist
7 maintained by UNOS, whose accrual of wait time was delayed because of the use of
8 the race-based coefficient, residing in California, and Cedars-Sinai is Plaintiff's
9 designated transplant hospital.

10 75. Plaintiff's claims are typical of the other members of the classes because
11 all class members were injured as a result of substantially similar conduct by UNOS
12 and Cedars-Sinai.

13 76. Plaintiff is an adequate class representative because his interests do not
14 conflict with the interests of the other members of the classes. Plaintiff has retained
15 counsel competent and experienced in complex class action litigation, and Plaintiff
16 intends to prosecute this action vigorously. The class's and subclass's interests will
17 be fairly and adequately protected by Plaintiff and his counsel.

18 77. The prosecution of separate actions by individual members of the class
19 and subclasses would create a risk of inconsistent or varying adjudications.

20 78. The questions of law and fact common to the members of the classes and
21 subclasses predominate over any questions of law or fact affecting only individual
22 members of the classes and subclasses. The primary claims to be proven in this case
23 relate to whether UNOS and Cedars-Sinai engaged in actionable discriminatory
24 behavior by virtue of their use of the race-based coefficient and manipulated wait
25 times in the formula to determine which patient receives a donor kidney. Moreover,
26 the types of damages suffered by class members, such as increased dialysis costs, are
27 uniform and can be calculated on a class-wide basis. These issues predominate over
28 any individual issues, of which there appear to be few if any.

1 79. A class action is superior to other available methods for the fair and
 2 efficient adjudication of this controversy. Treatment as a class action will permit a
 3 large number of similarly situated persons to adjudicate their common claims in a
 4 single forum simultaneously, efficiently, and without the duplication of effort and
 5 expense that numerous individual actions would engender. Prosecution as a class
 6 action will eliminate the need for repetitious litigation—if it were even feasible for
 7 each member of the class and subclasses to proceed individually.

8 80. Plaintiff is not aware of any similar cases filed against UNOS or Cedars-
 9 Sinai.

10 81. California is a proper and desirable forum for the claims against UNOS
 11 and Cedars-Sinai to proceed. UNOS maintains the national kidney waitlist, but more
 12 than 23,000 members of that waitlist reside in California, a significant percentage of
 13 all members of the waitlist. Moreover, Cedars-Sinai and the Plaintiff are both located
 14 in California, and all the members of the subclasses are located in California.

15 82. The classes and subclasses are readily definable by review of medical
 16 records that should exist in the files of UNOS and Cedars-Sinai. Moreover, UNOS
 17 and Cedars-Sinai should have records of the e-mail addresses, phone numbers, and
 18 addresses of members of the national kidney waitlist such that providing notice to the
 19 classes and subclasses will be practicable. Thus, there does not exist any significant
 20 likely difficulties in managing the claims as a class action.

21 **FIRST CAUSE OF ACTION**

22 **(Violation of Title VI of the Civil Rights Act of 1964)**

23 83. Plaintiff re-alleges and incorporates herein by reference, as though set
 24 forth in full, each of the allegations set forth in paragraphs 1 through 82 above.

25 84. This cause of action is brought by Plaintiff, the Nationwide Waitlist
 26 Class, the California Waitlist Class, and the Cedars-Sinai Class against UNOS.

27 85. UNOS receives significant financial assistance from the Federal
 28 government. Approximately 10% of UNOS's budget is provided by the Federal

1 government, in accordance with the National Organ Transplant Act's authorization of
2 \$7,000,000/year to fund a private, non-profit entity such as UNOS.

3 86. These contracts were intended by the Federal government to act as a
4 subsidy to UNOS, not as compensation for any goods or services provided by UNOS
5 to the Federal government, for which there are none.

6 87. UNOS has engaged in racial discrimination. As alleged in detail above,
7 UNOS allowed and encouraged use of the race-based coefficient to artificially inflate
8 Black patients' eGFR scores, thus delaying their accrual of wait time, and prejudicing
9 their chances of receiving a donor kidney.

10 88. UNOS further knowingly used these modified wait times for Black
11 patients in its UNet software, causing Black patients to be ranked lower for specific
12 donor kidneys vis-à-vis members of other races. Even after admitting the practice was
13 racially discriminatory, UNOS failed to take prompt action to ensure Black patients'
14 wait times were recalculated.

15 89. The above-described racial discrimination damaged Plaintiff and
16 members of the Nationwide Waitlist Class, the California Waitlist Class, and the
17 Cedars-Sinai Class by depriving and/or delaying their award of a donor kidney. This
18 has caused Plaintiff and members of the Nationwide Waitlist Class, the California
19 Waitlist Class, and the Cedars-Sinai Class to incur economic injuries, including but
20 not limited to, continued medical costs such as dialysis costs.

21 **SECOND CAUSE OF ACTION**

22 **(Violation of the Unruh Civil Rights Act [California Civil Code § 51])**

23 90. Plaintiff re-alleges and incorporates herein by reference, as though set
24 forth in full, each of the allegations set forth in paragraphs 1 through 89 above.

25 91. This cause of action is brought by Plaintiff and members of the California
26 Waitlist Class and the Cedars-Sinai Class against UNOS and Cedars-Sinai.

27 92. Both UNOS and Cedars-Sinai are "business establishments" as defined
28 by the Unruh Civil Rights Act.

1 93. Both UNOS and Cedars-Sinai have engaged in racial discrimination
2 against citizens of California, within California. As to UNOS, as alleged in detail
3 above, UNOS allowed and encouraged use of the race-based coefficient to artificially
4 inflate the eGFR scores of Black patients located within California, thus delaying their
5 accrual of wait time, and prejudicing their chances to receive a donor kidney.

6 94. UNOS further knowingly used these modified wait times for Black
7 patients within California in its UNet software, causing said Black patients to be
8 ranked lower for specific donor kidneys vis-à-vis members of other races. Even after
9 admitting the practice was racially discriminatory, UNOS failed to take prompt action
10 to ensure Black patients' wait times were recalculated.

11 95. Cedars-Sinai knowingly submitted eGFR scores tainted by use of the
12 race-based coefficient to UNOS for inclusion in its UNet algorithm, prejudicing its
13 own Black patients' chances to receive a donor kidney. Even after UNOS changed
14 course and outlawed use of the race-based coefficient, Cedars-Sinai failed for more
15 than nine months to take any action to recalculate its Black patients' wait times.

16 96. Both Cedars-Sinai and the members of the California Waitlist Class and
17 Cedars-Sinai Class are located within California.

18 97. The above-described racial discrimination damaged Plaintiff and
19 members of the California Waitlist Class and the Cedars-Sinai Class by depriving
20 and/or delaying their award of a donor kidney. This has caused Plaintiff and members
21 of the California Waitlist Class and the Cedars-Sinai Class to incur economic injuries,
22 including but not limited to, continued medical costs such as dialysis costs.

23 **THIRD CAUSE OF ACTION**

24 **(Breach of Fiduciary Duty)**

25 98. Plaintiff re-alleges and incorporates herein by reference, as though set
26 forth in full, each of the allegations set forth in paragraphs 1 through 97 above.

27 99. This cause of action is brought by Plaintiff and members of the
28 Nationwide Waitlist Class, the California Waitlist Class, and the Cedars-Sinai Class

1 against Cedars-Sinai.

2 100. As the transplant hospital for Plaintiff and members of the Cedars-Sinai
3 Class, Cedars-Sinai owed Plaintiff and members of the Cedars-Sinai Class a fiduciary
4 duty.

5 101. Cedars-Sinai breached its fiduciary duty by engaging in racial
6 discrimination against its fiduciaries.

7 102. Cedars-Sinai breached its fiduciary duty by knowingly submitting eGFR
8 scores tainted by use of the race-based coefficient to UNOS for inclusion in its UNet
9 algorithm, prejudicing its own Black patients' chances to receive a donor kidney.
10 Even after UNOS changed course and outlawed use of the race-based coefficient,
11 Cedars-Sinai failed for more than nine months to take any action to recalculate its
12 Black patients' wait times.

13 103. The above-described breaches of fiduciary duty damaged Plaintiff and
14 members of the Nationwide Waitlist Class, the California Waitlist Class, and the
15 Cedars-Sinai Class by depriving and/or delaying their award of a donor kidney. This
16 has caused Plaintiff and members of the Nationwide Waitlist Class, the California
17 Waitlist Class, and the Cedars-Sinai Class to incur economic injuries, including but
18 not limited to, continued medical costs such as dialysis costs.

19 **FOURTH CAUSE OF ACTION**

20 **(Violation of California's Unfair Competition Law [Cal. Bus. & Prof. Code §** 21 **17200 et seq.]**

22 104. Plaintiff re-alleges and incorporates herein by reference, as though set
23 forth in full, each of the allegations set forth in paragraphs 1 through 105 above.

24 105. This cause of action is brought by Plaintiff and members of the California
25 Waitlist Class and the Cedars-Sinai Class against UNOS and Cedars-Sinai.

26 106. UNOS and Cedars-Sinai have committed acts of unfair competition, as
27 defined by California Business and Professions Code § 17200, by engaging in the
28 unlawful and discriminatory practices described above. Without limitation, UNOS

1 and Cedars-Sinai have discriminated against Black patients by their use of the race-
 2 based coefficient, which fails to give Black patients credit for the appropriate amount
 3 of wait time.

4 107. This failure to properly calculate wait time has harmed Plaintiff, the
 5 California Waitlist Class, and the Cedars-Sinai Class, because their chances to receive
 6 a donor kidney have been lessened. Indeed, as alleged above, on information and
 7 belief, Plaintiff was deprived of a donor kidney because UNOS and Cedars-Sinai used
 8 a wait time calculation tainted by application of the race-based coefficient.

9 108. Plaintiff and the members of the California Waitlist Class and Cedars-
 10 Sinai Class all reside in California, and the discrimination against these persons
 11 occurred in California. Cedars-Sinai is also located in California, and its alleged
 12 discriminatory conduct occurred in California.

13 109. Plaintiff paid to Defendants a significant registration fee, required to join
 14 UNOS's national kidney waitlist.

15 110. Plaintiff and the members of the California Waitlist Class and Cedars-
 16 Sinai Class are without an adequate remedy at law.

17 **PRAYER FOR RELIEF**

18 WHEREFORE, Plaintiff and the putative Nationwide Waitlist Class, California
 19 Waitlist Class, and Cedars-Sinai Class pray for relief against UNOS and Cedars-Sinai
 20 as follows:

- 21 1. For damages in compensation for the economic injuries suffered by the
- 22 Plaintiff, the Nationwide Waitlist Class, California Waitlist Class, and Cedars-Sinai
- 23 Class, in an amount to be determined by evidence, but in excess of \$5 million;
- 24 2. For statutory damages and treble damages as allowed by the Unruh Act;
- 25 3. For restitution of registration fees paid to UNOS;
- 26 4. For punitive damages in an amount according to proof;
- 27 5. For pre-judgment interest on all damages awarded by this Court;
- 28 6. For reasonable attorneys' fees and costs of suit incurred herein; and

1 7. For such other and further relief as the Court deems just and proper.

2
3 Dated: March 29, 2024

ELLIS GEORGE LLP

Matthew L. Venezia

George B. A. Laiolo

5
6 By: /s/ Matthew L. Venezia

Matthew L. Venezia

7 Attorneys for Plaintiff Anthony Randall

DEMAND FOR JURY TRIAL

Plaintiff hereby demands a jury trial as provided by Rule 38(a) of the Federal Rules of Civil Procedure.

Dated: March 29, 2024

ELLIS GEORGE LLP

Matthew L. Venezia

George B. A. Laiolo

By: /s/ Matthew L. Venezia

Matthew L. Venezia

Attorneys for Plaintiff Anthony Randall

2397290.1

EXHIBIT A

1 ELLIS GEORGE ~~CIPOLLONE~~
2 ~~O'BRIEN-ANNAGUEY-LLP~~
3 Matthew L. Venezia (State Bar No. 313812)
4 mvenezia@~~bgr~~firmellisgeorge.com
5 George B. A. Laiolo (State Bar No. 329850)
6 glaiolo@~~ege~~firmellisgeorge.com
7 2121 Avenue of the Stars, 30th Floor
8 Los Angeles, California 90067
9 Telephone: (310) 274-7100
10 Facsimile: (310) 275-5697

11 Attorneys for Plaintiff
12 ~~Anthony Randall~~ ANTHONY RANDALL

13 UNITED STATES DISTRICT COURT
14 CENTRAL DISTRICT OF CALIFORNIA
15 WESTERN DIVISION

16 ANTHONY RANDALL,
17 Plaintiff,

18 vs.

19 UNITED NETWORK FOR ORGAN
20 SHARING; CEDARS-SINAI
21 MEDICAL CENTER,
22 Defendants.

Case No. 2:23-CV-02576-MEMF (MAAx)

~~FIRST~~SECOND AMENDED
COMPLAINT FOR:

(1) VIOLATION OF TITLE VI OF
THE CIVIL RIGHTS ACT OF 1964;

(2) VIOLATION OF THE UNRUH
CIVIL RIGHTS ACT [CALIFORNIA
CIVIL CODE § 51];

(3) BREACH OF FIDUCIARY DUTY;
AND

(4) VIOLATION OF CALIFORNIA'S
UNFAIR COMPETITION LAW [CAL.
BUS. & PROF. CODE § 17200 ET
SEQ.]

Action Filed: April 5, 2023

1 Plaintiff Anthony Randall (“Plaintiff”) brings this Complaint individually, and
 2 on behalf of all persons similarly situated, against the United Network for Organ
 3 Sharing and Cedars-Sinai Medical Center (“Defendants”), and alleges as follows:

4 **INTRODUCTION**

5 1. Black Americans are more than three times as likely to suffer from
 6 kidney failure when compared to White Americans. As a group, and as a result of
 7 ongoing racial inequality, Black Americans are at higher risk for maladies such as
 8 high blood pressure, obesity, diabetes, and heart disease, each of which increase the
 9 likelihood of suffering kidney disease.

10 2. Despite being overrepresented when it comes to kidney disease, and
 11 overrepresented on the national waitlist for donor kidneys, Black Americans are much
 12 less likely than their White counterparts to actually receive a kidney transplant.

13 3. Kidney function is measured by an estimated glomerular filtration rate
 14 test, commonly referred to as eGFR. A patient’s eGFR score is used to determine
 15 when the patient is eligible to begin accruing wait time on the national kidney waitlist,
 16 with the score needing to fall below 20 ml/min to qualify a patient to begin ~~to~~
 17 ~~accrue~~accruing wait time.

18 4. When current tests for the eGFR were developed, a few flawed studies
 19 indicated Black Americans had higher creatinine extraction rates, and instead of
 20 considering whether this difference could be caused by non-racial societal factors, it
 21 was postulated by the developers of the eGFR that Black Americans’ scores could be
 22 explained because Black Americans have more muscle mass and thus more creatinine
 23 in their systems than White Americans.

24 5. Based on this postulation, the creators of the eGFR added a race-based
 25 modifier to eGFR scores, known as the “race-based coefficient,” which artificially
 26 inflates the scores of Black Americans by 16–18%. That is, eGFR is calculated
 27 irrespective of race, and then only for Black patients, the score is increased by 16–
 28 18%, based upon the flawed premise that Black Americans have greater muscle mass

1 and thus naturally have more creatinine in their bodies.

2 6. This, of course, is junk science supported only by racial stereotypes, and
 3 not any valid scientific studies. As described in an article titled *Systemic Kidney*
 4 *Transplant Inequities for Black Individuals: Examining the Contribution of*
 5 *Racialized Kidney Function Estimating Equations*, the theory supporting the race-
 6 based modification to Black patients' eGFR scores has "not been substantiated by
 7 rigorous scientific evidence[.]"

8 7. Indeed, the United Network for Organ Sharing ("UNOS") recently
 9 admitted as much, posting the following passage on its website:



Organ donors

Patients

What are other issues with the race variable in eGFR?

EGFR calculations rely on a binary approach to race. When the race variable is used in formulas, eGFR calculators only offer two response options: "Black" or "Not Black."

These options do not include a designation for mixed race or multi-racial individuals, and do not account for the existing genetic diversity within the Black population. The concept of race is a social construct and an unreliable proxy for genetic difference, therefore not a biological marker or clinical measure.

10
11
12
13
14
15
16
17
18
19
20 8. This is important because eGFR scores are used to determine when a
 21 patient is eligible to begin accruing wait time on the national kidney waitlist,
 22 maintained by UNOS, and wait time is a key factor in determining which patient will
 23 be awarded a kidney, as kidneys become available. Again, for an eGFR score to
 24 qualify a patient with kidney disease to accrue wait time, the eGFR score must fall
 25 below 20 ml/min.

26 9. However, until recently, application of the race-based coefficient
 27 artificially increased Black patients' eGFR scores above that threshold such that Black
 28 patients' unmodified eGFR scores must have fallen well below 20 ml/min before they

1 began accruing wait time.

2 10. Indeed, because of the race-based coefficient, many Black patients never
3 began to accrue wait time because of a qualifying eGFR score, but were instead
4 delayed until such time as they were forced to begin dialysis, the other possible
5 triggering factor for wait time, which is recommended when kidney function falls
6 below 15 ml/min, or when certain symptoms of kidney disease present themselves.

7 11. It is true that UNOS recently announced it was outlawing use of the race-
8 based coefficient when measuring eGFR scores. UNOS's announcements rightly
9 admit the discriminatory nature of their past policy, but will also prove too little too
10 late for many Black Americans currently suffering kidney failure.

11 12. In this regard, UNOS announced its intent to change course and outlaw
12 use of the race-based coefficient in June of 2022, but did nothing for more than six
13 months to address the erroneous wait time calculations for Black Americans already
14 on the national kidney waitlist.

15 13. In January of 2023, UNOS did instruct donor hospitals to notify Black
16 candidates of the policy change and investigate whether Black members of their donor
17 lists were eligible for a wait time modification, but UNOS gave donor hospitals a year
18 to complete this process, until January of 2024.

19 14. Indeed, Cedars-Sinai, the donor hospital for Plaintiff and 205 other Black
20 Americans suffering from kidney disease, took no steps whatsoever to address
21 erroneous wait time calculations, until March 27, 2023, when it advised members of
22 its waitlist that the issue would be considered over "[o]ver the next several months[.]"

23 15. Unfortunately, in the time between June of 2022 and January of 2024,
24 tens of thousands of Black Americans will be prejudiced in their candidacy for a donor
25 kidney by use of erroneous wait time calculations, missing out on donor kidneys they
26 rightfully should have been awarded, incurring significant economic losses, suffering
27 from worsened kidney disease, and in some instances, dying.

28 16. In other words, many Black Americans suffering from kidney disease

1 did not have 18 months for UNOS to fix its wait time calculations, and during this
 2 period, Black Americans continue to suffer racial discrimination in the kidney
 3 donation process, despite all involved admitting that the current process is
 4 discriminatory to Black Americans.

5 17. Plaintiff Anthony Randall is one such Black American that ~~is~~
 6 ~~currently~~was on UNOS's national kidney transplant waitlist. Plaintiff, having suffered
 7 previous symptoms of kidney failure, took monthly eGFR tests for years, until such
 8 time as his eGFR score, despite continued application of the race-based coefficient,
 9 was low enough for him to begin accruing wait time on the national kidney waitlist.

10 18. Plaintiff ~~has now been~~was on the national kidney transplant waitlist for
 11 more than five years, but upon information and belief, ~~could~~should have qualified to
 12 accrue wait time years earlier absent application of the race-based coefficient. As
 13 recently as December of 2022, Plaintiff was advised he "finished second" for a
 14 kidney, but upon information and belief, had Plaintiff's wait time been properly
 15 calculated, without regard to his race, Plaintiff would have ~~already~~ received a
 16 transplant kidney in December of 2022, or earlier.

17 19. New donor kidneys become available on a daily basis, and as ~~Plaintiff's~~
 18 ~~health~~the health of Black patients on the waitlist deteriorates ~~and he continues on~~
 19 ~~dialysis~~, the failure to properly calculate ~~Plaintiff's proper~~Black patients' wait time
 20 such that ~~he~~they can be fairly considered for kidneys as they become available ~~truly~~
 21 ~~jeopardizes his life. The same~~jeopardize their lives. This is true for the other 205
 22 Black patients at Cedars-Sinai, and approximately 27,500 Black members of the
 23 national kidney waitlist.

PARTIES

20. Plaintiff Anthony Randall is an individual residing in Los Angeles, California.

21. Plaintiff is informed and believes, and thereon alleges, that Defendant UNOS is a Virginia nonprofit corporation with its principal place of business in Richmond, Virginia.

22. Plaintiff is informed and believes, and thereon alleges, that Defendant Cedars-Sinai Medical Center (“Cedars-Sinai”) is a California nonprofit corporation with its principal place of business in Los Angeles, California.

JURISDICTION AND VENUE

23. This Court has federal question jurisdiction over this matter pursuant to 28 U.S.C. §§ 1331, 1332(d), and 1343 because Plaintiff asserts a federal cause of action alleging racial discrimination, and because at least one member of the putative classes defined hereinafter is a citizen of a different state than all Defendants, and the amount in controversy exceeds \$5,000,000. This Court further has supplemental jurisdiction over any state law claims pursuant to 28 U.S.C. § 1367.

24. Venue in this district is proper pursuant to 28 U.S.C. § 1391 because Plaintiff resides in this District and has been affected by Defendants’ unlawful policies and procedures within the District, Cedars-Sinai’s principal place of business is within this District, and Cedars-Sinai’s alleged actions have occurred within the District. Defendants also apply their unlawful policies and procedures to additional putative class members residing within the District. Thus, a substantial part of the events or omissions that gave rise to the claims asserted herein occurred within this District.

25. This Court has personal jurisdiction over UNOS because UNOS conducts operations within California by virtue of its management of the kidney donor list for all patients residing within the State, including Plaintiff. UNOS makes decisions as to which patients residing in California will be offered donor kidneys.

1 considers the information maintained in UNet, and generates a list of potential
 2 matches, ranking potential matches on the national kidney waiting list. These kidneys
 3 are then offered to patients through the transplant hospitals, in accordance with the
 4 UNet-generated rankings.

5 32. Upon information and belief, the primary factor considered by UNet's
 6 algorithm to rank candidates for potentially compatible kidneys is a patient's accrued
 7 wait time. In other words, UNet will identify patients that are a medical match for a
 8 particular available kidney, and then rank those patients according to wait time.

9 33. Importantly, referral to the waitlist does not automatically start the clock
 10 on qualifying wait time. To accrue qualifying wait time, generally a patient's eGFR
 11 score must either fall below 20 ml/min, or the patient must begin dialysis.

12 **B. The Defendants applied a racially discriminatory coefficient to**
 13 **eGFR scores for Black patients.**

14 34. Again, UNOS is responsible for enacting policy concerning the selection
 15 of which patients receive which donor kidneys. In this regard, UNOS offers as one
 16 ~~if~~of its strategic goals to "[p]rovide equity in access to transplants[.]" UNOS has fallen
 17 far short of its stated goal.

18 35. For decades, the race-based coefficient was applied to artificially inflate
 19 eGFR scores for Black Americans, overstating their kidney function by 16–18%,
 20 based upon the underlying assumption that Black Americans have greater muscle
 21 mass and thus naturally have more creatinine in their system.

22 36. As noted above, patients do not begin accruing wait time on the national
 23 kidney waitlist until their eGFR score reaches 20 ml/min. But for Black patients, even
 24 when their unadjusted eGFR score fell below 20 ml/min, the race-based coefficient
 25 was applied to artificially inflate the Black patients' eGFR scores above 20 ml/min,
 26 preventing them from qualifying to accrue wait time. Thus, Black patients' eGFR
 27 scores had to fall well below 20 ml/min before they began to accrue wait time.

28 37. UNOS policy encouraged and allowed for use of the race-based

1 coefficient, and UNOS knowingly used modified eGFR scores and manipulated wait
2 times when ranking patients for kidney transplants. Specifically, UNOS is and has at
3 all times been aware that its UNet software includes an algorithm that uses wait time
4 as the primary factor in ranking patients for donor kidneys, and that its UNet software
5 includes wait times for Black patients that have been manipulated by use of the race-
6 based coefficient. To be clear, this modification was made to Black patients' eGFR
7 scores entirely because of their race, and was not applied to other racial groups.

8 38. There has never been any serious scientific research to support use of the
9 race-based coefficient to artificially increase Black patients' eGFR scores. Instead,
10 the race-based coefficient is based on eugenics-style racism and stereotypes that
11 assume Black Americans are more physically fit than White Americans and other
12 racial groups.

13 39. Years before UNOS took any action to review its policy allowing for use
14 of the race-based coefficient, the practice was criticized by doctors for its racially
15 discriminatory nature. For example, in November of 2011, Dr. Toni Martin published
16 an article in the *American Journal of Kidney Diseases* that questioned the practice,
17 explaining that when she attempts to explain the policy to Black patients, she "get[s]
18 a snort of disbelief[,]” and noting the history of purported genetic differences being
19 used against Black Americans against a backdrop of “separate and unequal.”

20 40. Use of the race-based coefficient seriously diminishes Black patients'
21 chances to receive a donor kidney, and for Black patients that defeat the odds and
22 ultimately receive a kidney from the national waitlist, their waiting time is still
23 increased. Indeed, because of this eGFR manipulation, many Black patients never
24 qualified to accrue wait time because of their eGFR score, and only began to accrue
25 wait time when they began dialysis.

26 41. All other factors being equal, the above-described practices have resulted
27 in non-Black patients receiving numerous kidneys that would otherwise have been
28 given to Black applicants had their wait time been calculated without consideration

1 of race.

2 42. The failure to receive donor kidneys has caused significant harm to Black
3 Americans. The unfortunate reality is that many Black Americans have already passed
4 away that would have survived if given fair consideration for a donor kidney.

5 43. Other Black Americans have suffered worsened kidney disease and/or
6 been forced to go on dialysis because of the lengthened wait time for a donor kidney.
7 These Black Americans have suffered economic damages in the form of medical
8 expenses and lost wages.

9 **C. Even after UNOS admitted the race-based coefficient discriminates**
10 **against Black Americans, Defendants failed to timely address the**
11 **problem.**

12 44. In June of 2022, UNOS admitted the racially discriminatory nature of
13 the race-based coefficient for Black Americans, approving “a measure to require
14 transplant hospitals to use a race-neutral calculation when estimating a patient’s level
15 of kidney function.” In its press release, UNOS explained that

16 For a number of years, some eGFR calculations have
17 included a modifier for patients identified as Black. This
18 practice has led to a systemic underestimation of kidney
19 disease severity for many Black patients. Specifically in
organ transplantation, it may have negatively affected the
timing of transplant listing or the date at which candidates
qualify to begin waiting time for a transplant.²

20 45. UNOS policy officially changed on July 27, 2022, with UNOS policy
21 prior to that time expressly allowing for use of the race-based coefficient to artificially
22 increase Black patients’ eGFR scores.

23 46. Nonetheless, UNOS continued to use the race-based coefficient as a
24 default. For more than six months, UNOS took no affirmative steps to adjust wait
25 times and correct for previous use of the race-based coefficient.

26 47. On January 5, 2023, UNOS announced a new policy that would require
27

28 ² This Press release is publicly available at <https://unos.org/news/optn-board-approves-elimination-of-race-based-calculation-for-transplant-candidate-listing/>.

1 donor hospitals to provide two notifications to patients on the national kidney waitlist,
 2 one notifying patients that Black Americans will be considered for wait time
 3 adjustments where the race-based coefficient delayed their accrual of wait item, and
 4 a second notification confirming this process was completed and informing patients
 5 of their status. UNOS also directed donor hospitals to investigate which patients are
 6 eligible for a wait time adjustment, and request said adjustments within a year, i.e.,
 7 by January of 2024.

8 48. While this adjustment in policy rightfully acknowledges the problem, it
 9 ~~lacks~~lacked required urgency, and for the 27,500 Black Americans ~~currently~~ on the
 10 national kidney waitlist, such as Plaintiff, the policy change is too little too late.
 11 UNOS's policy concerning the race-based coefficient to eGFR scores was racially
 12 discriminatory before UNOS ever acknowledged the problem, and instead of making
 13 immediate changes, UNOS allowed member transplant hospitals approximately 18
 14 months to identify and attempt to correct falsely-calculated wait times.

15 49. During this period, Black Americans ~~continue~~continued to suffer a race-
 16 based disadvantage in their candidacy for a donor kidney—UNet continuing to utilize
 17 the old, improperly calculated wait times when awarding kidneys.

18 50. UNOS ultimately failed to process wait-time adjustments as promised.
 19 As of January 15, 2024, UNOS had completed only 14,849 wait-time adjustments
 20 where there are approximately 27,500 Black Americans currently on the waitlist.

21 **D. Plaintiff has been discriminated against by the race-based**
 22 **coefficient to eGFR scores for years, and has never been awarded a**
 23 **kidney.**

24 51. ~~50.~~ Plaintiff first discovered that he suffered from kidney disease
 25 approximately 24 years ago when he became ill and passed out, while in San Diego,
 26 California. For many years thereafter, Plaintiff's kidney disease was managed with
 27 medications.

28 52. ~~51.~~ However, having been diagnosed with kidney disease, Plaintiff

1 underwent monthly testing of his eGFR to determine his kidney function. Upon
 2 information and belief, at all times the race-based coefficient was used to artificially
 3 inflate Plaintiff's eGFR scores.

4 53. ~~52.~~ Plaintiff's artificially inflated eGFR scores first qualified Plaintiff to
 5 begin accruing wait time on the national kidney waitlist in January of 2018. Plaintiff
 6 has remained on the waitlist since that time, now having been on the list for more than
 7 five years, but has never been awarded a donor kidney.

8 54. ~~53.~~ Upon information and belief, Plaintiff's non-modified eGFR score
 9 fell below 20 ml/min, as is required to begin to accrue wait time, well before January
 10 of 2018.

11 55. ~~54.~~ Accordingly, but for use of the race-based coefficient, Plaintiff would
 12 have begun to accrue wait time prior to January of 2018, entitling Plaintiff to an earlier
 13 spot in line that would have increased Plaintiff's chances to receive a donor kidney.

14 56. ~~55.~~ Upon information and belief, but for the application of the race-based
 15 coefficient to Plaintiff's eGFR score, Plaintiff would have ~~already~~ received a donor
 16 kidney from the national waitlist significantly earlier than his actual transplant,
 17 instead of having to rely on a private donor.

18 57. ~~56.~~ In this regard, in December of 2022, Plaintiff received a call from
 19 Cedars-Sinai telling him to rush to Cedars-Sinai because a donor kidney was located.
 20 Plaintiff was held at the hospital for 17 hours, prepped for surgery, including not
 21 eating or drinking, only to be told that the donor kidney had been awarded to and
 22 implanted into another patient. Cedars-Sinai only then explained that Plaintiff had
 23 been requested to rush to the hospital as an alternate, and that the kidney had been
 24 given to the first choice.

25 58. ~~57.~~ However, at this time, Plaintiff's accrued wait time had not been
 26 recalculated to account for the delay caused by use of the race-based coefficient.
 27 Despite UNOS's clear admission in June of 2022 that the race-based coefficient is
 28 racially discriminatory towards Black Americans, neither UNOS nor Cedars-Sinai

1 had taken any steps by December of 2022 to recalculate Plaintiff's wait time
2 calculation.

3 59. ~~58.~~ Upon information and belief, but for the racially discriminatory
4 formula used to determine who would be awarded this particular kidney, resulting in
5 an improper calculation of Plaintiff's wait time, Plaintiff would have been awarded
6 and received a donor kidney in December of 2022, at the latest.

7 60. ~~59.~~ Indeed, Cedars-Sinai took no action whatsoever in response to
8 UNOS's recent policy change until March 27, 2023, when Cedars-Sinai sent notice
9 that it would begin reviewing members of its kidney wait list to determine whether
10 wait time adjustments were required "[o]ver the next several months[.]"

11 61. ~~60.~~ Because this first notice was required to be "sent before the
12 program's assessment of their list," and given the wording of the notice, it is clear that
13 even after UNOS announced the race-based coefficient may no longer be used,
14 Cedars-Sinai sat on its hands and did not even begin the process to evaluate whether
15 any of the members of its waitlist were entitled to a wait time adjustment for another
16 nine months.

17 ~~61. As of the filing of this lawsuit, upon information and belief, Plaintiff's~~
18 ~~wait time continues to be incorrectly calculated in UNOS's UNet software,~~
19 ~~prejudicing Plaintiff's candidacy for a donor kidney from the national kidney~~
20 ~~waitlist.~~

21 **E. As a result of not being awarded a kidney in the transplant market,**
22 **Plaintiff has suffered significant economic harms.**

23 62. Over the past years, Plaintiff's kidney disease has worsened
24 significantly. In January of 2022, Plaintiff's condition worsened to the point that he
25 became unable to work, and since that time, Plaintiff has been unable to return to
26 work. This has caused Plaintiff significant economic harm in the form of lost wages
27 and medical expenses, particularly ongoing dialysis costs.

CLASS ACTION ALLEGATIONS

63. Plaintiff brings this action on behalf of himself and the below-defined putative classes who are similarly situated under Rules 23(a), (b)(2), and (b)(3) of the Federal Rules of Civil Procedure.

64. The National Waitlist Class seeks damages and ~~injunctive relief, and~~ is defined as follows:

- All patients identified as Black on the national kidney waitlist, for whom the accrual of wait time was delayed by application of the race-based coefficient. This class excludes those patients pursuing personal injury or wrongful death claims.

65. Additionally, Plaintiff brings this action on behalf of the subclasses defined below.

66. The California Waitlist Class seeks damages and ~~injunctive relief, and~~ is defined as follows:

- All patients identified as Black on the national kidney waitlist, residing in California, for whom the accrual of wait time was delayed by application of the race-based coefficient. This class excludes those patients pursuing personal injury or wrongful death claims.

67. The Cedars-Sinai Waitlist Class seeks damages and ~~injunctive relief, and~~ is defined as follows:

- All patients identified as Black on the national kidney waitlist, for whom Cedars-Sinai was their designated transplant hospital, and for whom the accrual of wait time was delayed by application of the race-based coefficient. This class excludes those patients pursuing personal injury or wrongful death claims.

68. Upon information and belief, given that the national kidney waitlist includes approximately 27,500 Black Americans nationwide, the National Waitlist Class includes tens of thousands of members located throughout the United States.

69. Upon information and belief, given that there are more than 2,000 Black members of the national kidney waitlist residing in California, the California Waitlist Class includes thousands of members located in California.

70. Upon information and belief, and because Cedars-Sinai represents that

206 of its patients are potentially eligible for wait time adjustments, the Cedars-Sinai Class includes hundreds of members located in California.

71. The identities of the members of the National Waitlist Class, California Waitlist Class, and Cedars-Sinai Class are known or readily ascertainable by UNOS and Cedars-Sinai, and the number of persons who fall within the definition of these classes are so numerous and geographically dispersed as to make joinder of all members of the National Waitlist Class, California Waitlist Class, or Cedars-Sinai Class in their individual capacity impracticable, inefficient, and unmanageable so as to effectively deny each putative member of these classes his, her, or their right to obtain relief based on the claims and allegations made in this Complaint.

72. There are common questions of law and fact as to the National Waitlist Class, California Waitlist Class, and Cedars-Sinai Class, relating to and/or dispositive of the allegations of unlawful and misleading conduct made in the Complaint, and relating to and/or dispositive of the common pattern of alleged injury and harm caused by that unlawful and misleading conduct and sustained by the putative members of the classes, including, but not limited to:

- Whether UNOS discriminated against members of the classes on account of their race by encouraging and allowing for use of the race-based coefficient;
- Whether UNOS discriminated against members of the classes on account of their race by its knowing use of manipulated wait time data in the UNet algorithm;
- Whether UNOS's UNet algorithm was racially biased and led to delay for Black candidates seeking donor kidneys;
- Whether the disparate impact of UNOS's policy allowing for use of the race-based coefficient and the UNet algorithm was known to UNOS during the relevant time period, leading to the uniform disparate treatment of members of the classes;
- UNOS's knowledge of their practices and the discriminatory impact on the classes;
- ~~Whether UNOS owes members of the national kidney waiting list a fiduciary duty, and whether the use of the race-based coefficient and manipulated wait times violated such a duty held by members of the classes.~~

- 1 • Whether Cedars-Sinai discriminated against members of the Cedars-Sinai classes on account of their race by encouraging and allowing for
- 2 use of the race-based coefficient;
- 3 • Whether Cedars-Sinai discriminated against members of the Cedars-Sinai Class on account of their race by its failure to provide accurate wait
- 4 time data for inclusion in UNet;
- 5 • Whether Cedars-Sinai's failure to provide accurate wait time data for
- 6 inclusion in UNet was racially biased and led to delay for Black
- 7 candidates seeking donor kidneys;
- 8 • Whether the disparate impact of Cedars-Sinai's failure to provide
- 9 accurate wait time date for inclusion in UNet was known to Cedars-Sinai
- 10 during the relevant time period, leading to the uniform disparate
- 11 treatment of the Cedars-Sinai Class;
- 12 • Cedars-Sinai's knowledge of their practices and the discriminatory
- 13 impact on the Cedars-Sinai Class;
- 14 • Whether Cedars-Sinai owes its patients on the kidney waitlist a fiduciary
- 15 duty, and whether Cedars-Sinai's failure to provide accurate wait time
- 16 information for use in UNet violated such a duty; and
- 17 • The length of the delay caused by use of the race-based coefficient and
- 18 increased medical costs resulting therefrom.

19 73. The interests of Plaintiff and the classes are aligned. Plaintiff seeks to

20 establish that UNOS and Cedars-Sinai are liable for economic injuries caused to Black

21 patients by application the race-based coefficient. Should Plaintiff prevail in

22 establishing the same, each of the other members of the classes would then be entitled

23 to recover damages in compensation for their economic injuries.

24 74. The claims of Plaintiff are typical of the claims of the members of the

25 class and subclasses. Plaintiff is a Black member of the national kidney waitlist

26 maintained by UNOS, whose accrual of wait time was delayed because of the use of

27 the race-based coefficient, residing in California, and Cedars-Sinai is Plaintiff's

28 designated transplant hospital.

75. Plaintiff's claims are typical of the other members of the classes because

all class members were injured as a result of substantially similar conduct by UNOS

and Cedars-Sinai.

76. Plaintiff is an adequate class representative because his interests do not

1 conflict with the interests of the other members of the classes. Plaintiff has retained
2 counsel competent and experienced in complex class action litigation, and Plaintiff
3 intends to prosecute this action vigorously. The class's and subclass's interests will
4 be fairly and adequately protected by Plaintiff and his counsel.

5 77. The prosecution of separate actions by individual members of the class
6 and subclasses would create a risk of inconsistent or varying adjudications.

7 78. The questions of law and fact common to the members of the classes and
8 subclasses predominate over any questions of law or fact affecting only individual
9 members of the classes and subclasses. The primary claims to be proven in this case
10 relate to whether UNOS and Cedars-Sinai engaged in actionable discriminatory
11 behavior by virtue of their use of the race-based coefficient and manipulated wait
12 times in the formula to determine which patient receives a donor kidney. Moreover,
13 the types of damages suffered by class members, such as increased dialysis costs, are
14 uniform and can be calculated on a class-wide basis. These issues predominate over
15 any individual issues, of which there appear to be few if any.

16 79. A class action is superior to other available methods for the fair and
17 efficient adjudication of this controversy. Treatment as a class action will permit a
18 large number of similarly situated persons to adjudicate their common claims in a
19 single forum simultaneously, efficiently, and without the duplication of effort and
20 expense that numerous individual actions would engender. Prosecution as a class
21 action will eliminate the need for repetitious litigation—if it were even feasible for
22 each member of the class and subclasses to proceed individually.

23 80. Plaintiff is not aware of any similar cases filed against UNOS or Cedars-
24 Sinai.

25 81. California is a proper and desirable forum for the claims against UNOS
26 and Cedars-Sinai to proceed. UNOS maintains the national kidney waitlist, but more
27 than 23,000 members of that waitlist reside in California, a significant percentage of
28 all members of the waitlist. Moreover, Cedars-Sinai and the Plaintiff are both located

1 in California, and all the members of the subclasses are located in California.

2 82. The classes and subclasses are readily definable by review of medical
3 records that should exist in the files of UNOS and Cedars-Sinai. Moreover, UNOS
4 and Cedars-Sinai should have records of the e-mail addresses, phone numbers, and
5 addresses of members of the national kidney waitlist such that providing notice to the
6 classes and subclasses will be practicable. Thus, there does not exist any significant
7 likely difficulties in managing the claims as a class action.

8 **FIRST CAUSE OF ACTION**

9 **(Violation of Title VI of the Civil Rights Act of 1964)**

10 83. Plaintiff re-alleges and incorporates herein by reference, as though set
11 forth in full, each of the allegations set forth in paragraphs 1 through 82 above.

12 84. This cause of action is brought by Plaintiff, the Nationwide Waitlist
13 Class, the California Waitlist Class, and the Cedars-Sinai Class against UNOS.

14 85. UNOS receives significant financial assistance from the Federal
15 government. Approximately 10% of UNOS's budget is provided by the Federal
16 government, in accordance with the National Organ Transplant Act's authorization of
17 \$7,000,000/year to fund a private, non-profit entity such as UNOS.

18 86. These contracts were intended by the Federal government to act as a
19 subsidy to UNOS, not as compensation for any goods or services provided by UNOS
20 to the Federal government, for which there are none.

21 87. UNOS has engaged in racial discrimination. As alleged in detail above,
22 UNOS allowed and encouraged use of the race-based coefficient to artificially inflate
23 Black patients' eGFR scores, thus delaying their accrual of wait time, and prejudicing
24 their chances of receiving a donor kidney.

25 88. UNOS further knowingly used these modified wait times for Black
26 patients in its UNet software, causing Black patients to be ranked lower for specific
27 donor kidneys vis-à-vis members of other races. Even after admitting the practice was
28 racially discriminatory, UNOS failed to take prompt action to ensure Black patients'

1 wait times were recalculated.

2 89. The above-described racial discrimination damaged Plaintiff and
3 members of the Nationwide Waitlist Class, the California Waitlist Class, and the
4 Cedars-Sinai Class by depriving and/or delaying their award of a donor kidney. This
5 has caused Plaintiff and members of the Nationwide Waitlist Class, the California
6 Waitlist Class, and the Cedars-Sinai Class to incur economic injuries, including but
7 not limited to, continued medical costs such as dialysis costs.

8 **SECOND CAUSE OF ACTION**

9 **(Violation of the Unruh Civil Rights Act [California Civil Code § 51])**

10 90. Plaintiff re-alleges and incorporates herein by reference, as though set
11 forth in full, each of the allegations set forth in paragraphs 1 through 89 above.

12 91. This cause of action is brought by Plaintiff and members of the California
13 Waitlist Class and the Cedars-Sinai Class against UNOS and Cedars-Sinai.

14 92. Both UNOS and Cedars-Sinai are “business establishments” as defined
15 by the Unruh Civil Rights Act.

16 93. Both UNOS and Cedars-Sinai have engaged in racial discrimination
17 against citizens of California, within California. As to UNOS, as alleged in detail
18 above, UNOS allowed and encouraged use of the race-based coefficient to artificially
19 inflate the eGFR scores of Black patients located within California, thus delaying their
20 accrual of wait time, and prejudicing their chances to receive a donor kidney.

21 94. UNOS further knowingly used these modified wait times for Black
22 patients within California in its UNet software, causing said Black patients to be
23 ranked lower for specific donor kidneys vis-à-vis members of other races. Even after
24 admitting the practice was racially discriminatory, UNOS failed to take prompt action
25 to ensure Black patients’ wait times were recalculated.

26 95. Cedars-Sinai knowingly submitted eGFR scores tainted by use of the
27 race-based coefficient to UNOS for inclusion in its UNet algorithm, prejudicing its
28 own Black patients’ chances to receive a donor kidney. Even after UNOS changed

1 course and outlawed use of the race-based coefficient, Cedars-Sinai failed for more
2 than nine months to take any action to recalculate its Black patients' wait times.

3 96. Both Cedars-Sinai and the members of the California Waitlist Class and
4 Cedars-Sinai Class are located within California.

5 97. The above-described racial discrimination damaged Plaintiff and
6 members of the California Waitlist Class and the Cedars-Sinai Class by depriving
7 and/or delaying their award of a donor kidney. This has caused Plaintiff and members
8 of the California Waitlist Class and the Cedars-Sinai Class to incur economic injuries,
9 including but not limited to, continued medical costs such as dialysis costs.

10 **THIRD CAUSE OF ACTION**

11 **(Breach of Fiduciary Duty)**

12 98. Plaintiff re-alleges and incorporates herein by reference, as though set
13 forth in full, each of the allegations set forth in paragraphs 1 through 97 above.

14 99. This cause of action is brought by Plaintiff and members of the
15 Nationwide Waitlist Class, the California Waitlist Class, and the Cedars-Sinai Class
16 against ~~UNOS and~~ Cedars-Sinai.

17 ~~100. As the steward of the national kidney waitlist and the candidacy for a~~
18 ~~donor kidney for the Plaintiff and members of the Nationwide Waitlist Class, the~~
19 ~~California Waitlist Class, and the Cedars-Sinai Class, UNOS owed Plaintiff and~~
20 ~~members of the Nationwide Waitlist Class, the California Waitlist Class, and the~~
21 ~~Cedars-Sinai Class a fiduciary duty.~~

22 100. ~~101.~~ As the transplant hospital for Plaintiff and members of the Cedars-
23 Sinai Class, Cedars-Sinai owed Plaintiff and members of the Cedars-Sinai Class a
24 fiduciary duty.

25 101. ~~102.~~ Both UNOS and Cedars-Sinai breached ~~their~~its fiduciary ~~duties~~duty
26 by engaging in racial discrimination against ~~their~~its fiduciaries. ~~As to UNOS, as~~
27 ~~alleged in detail above, UNOS allowed and encouraged use of the race-based~~
28 ~~coefficient to artificially inflate the eGFR scores of Black patients located within~~

1 ~~California, thus delaying their accrual of wait time, and prejudicing their chances to~~
 2 ~~receive a donor kidney.~~

3 ~~103. UNOS further knowingly used these modified wait times for Black~~
 4 ~~patients within California in its UNet software, causing said Black patients to be~~
 5 ~~ranked lower for specific donor kidneys vis-à-vis members of other races. Even after~~
 6 ~~admitting the practice was racially discriminatory, UNOS failed to take prompt~~
 7 ~~action to ensure Black patients' wait times were recalculated.~~

8 102. ~~104.~~ Cedars-Sinai breached its fiduciary duty by knowingly submitting
 9 eGFR scores tainted by use of the race-based coefficient to UNOS for inclusion in its
 10 UNet algorithm, prejudicing its own Black patients' chances to receive a donor
 11 kidney. Even after UNOS changed course and outlawed use of the race-based
 12 coefficient, Cedars-Sinai failed for more than nine months to take any action to
 13 recalculate its Black patients' wait times.

14 103. ~~105.~~ The above-described breaches of fiduciary duty damaged Plaintiff
 15 and members of the Nationwide Waitlist Class, the California Waitlist Class, and the
 16 Cedars-Sinai Class by depriving and/or delaying their award of a donor kidney. This
 17 has caused Plaintiff and members of the Nationwide Waitlist Class, the California
 18 Waitlist Class, and the Cedars-Sinai Class to incur economic injuries, including but
 19 not limited to, continued medical costs such as dialysis costs.

20 **FOURTH CAUSE OF ACTION**

21 **(Violation of California's Unfair Competition Law [Cal. Bus. & Prof. Code §**
 22 **17200 et seq.])**

23 104. ~~106.~~ Plaintiff re-alleges and incorporates herein by reference, as though
 24 set forth in full, each of the allegations set forth in paragraphs 1 through 105 above.

25 105. ~~107.~~ This cause of action is brought by Plaintiff and members of the
 26 California Waitlist Class and the Cedars-Sinai Class against UNOS and Cedars-Sinai.

27 106. ~~108.~~ UNOS and Cedars-Sinai have committed acts of unfair competition,
 28 as defined by California Business and Professions Code § 17200, by engaging in the

1 unlawful and discriminatory practices described above. Without limitation, UNOS
 2 and Cedars-Sinai have discriminated against Black patients by their use of the race-
 3 based coefficient, which fails to give Black patients credit for the appropriate amount
 4 of wait time.

5 107. ~~109.~~ This failure to properly calculate wait time has harmed Plaintiff, the
 6 California Waitlist Class, and the Cedars-Sinai Class, because their chances to receive
 7 a donor kidney have been lessened. Indeed, as alleged above, on information and
 8 belief, Plaintiff was deprived of a donor kidney because UNOS and Cedars-Sinai used
 9 a wait time calculation tainted by application of the race-based coefficient.

10 108. ~~110.~~ Plaintiff and the members of the California Waitlist Class and
 11 Cedars-Sinai Class all reside in California, and the discrimination against these
 12 persons occurred in California. Cedars-Sinai is also located in California, and its
 13 alleged discriminatory conduct occurred in California.

14 109. Plaintiff paid to Defendants a significant registration fee, required to join
 15 UNOS's national kidney waitlist.

16 110. ~~111.~~ Plaintiff and the members of the California Waitlist Class and
 17 Cedars-Sinai Class are without an adequate remedy at law.

18 **PRAYER FOR RELIEF**

19 WHEREFORE, Plaintiff and the putative Nationwide Waitlist Class, California
 20 Waitlist Class, and Cedars-Sinai Class pray for relief against UNOS and Cedars-Sinai
 21 as follows:

22 ~~1. For preliminary and permanent injunctions enjoining and restraining~~
 23 ~~UNOS and Cedars-Sinai, their agents, employees, representatives, partners, joint~~
 24 ~~venturers, and/or anyone acting on behalf of, or in concert with UNOS or Cedars-~~
 25 ~~Sinai, from engaging in the above-described racial discrimination and breaches of~~
 26 ~~fiduciary duty;~~

27 1. ~~2.~~ For damages in compensation for the economic injuries suffered by
 28 the Plaintiff, the Nationwide Waitlist Class, California Waitlist Class, and Cedars-

1 Sinai Class, in an amount to be determined by evidence, but in excess of \$5 million;
2 2. ~~3.~~ For statutory damages and treble damages as allowed by the Unruh
3 Act;

4 3. For restitution of registration fees paid to UNOS;

5 4. For punitive damages in an amount according to proof;

6 5. For pre-judgment interest on all damages awarded by this Court;

7 6. For reasonable attorneys' fees and costs of suit incurred herein; and

8 7. For such other and further relief as the Court deems just and proper.
9

10 ~~DATED:~~Dated: March 29, 2024 ELLIS GEORGE ~~CIPOLLONE~~

11 ~~O'BRIEN-ANNAGUEY~~ LLP

12 Matthew L. Venezia

13 George B. A. Laiolo

14 By: /s/ Matthew L. Venezia

15 Matthew L. Venezia

16 Attorneys for Plaintiff Anthony Randall
17
18
19
20
21
22
23
24
25
26
27
28

DEMAND FOR JURY TRIAL

Plaintiff hereby demands a jury trial as provided by Rule 38(a) of the Federal Rules of Civil Procedure.

~~DATED:~~Dated: March 29, 2024 ELLIS GEORGE ~~CIPOLLONE~~
~~O'BRIEN-ANNAGUEY~~ LLP
Matthew L. Venezia
George B. A. Laiolo

By: ~~/s/ Matthew L. Venezia~~
Matthew L. Venezia
~~George B. A. Laiolo~~
Attorneys for Plaintiff Anthony Randall

2397290.1

Summary report: Litera Compare for Word 11.4.0.111 Document comparison done on 3/29/2024 12:34:45 PM	
Style name: Default Style	
Intelligent Table Comparison: Active	
Original filename: First Amended Complaint(2224171.1).docx	
Modified filename: 2024-03-29 Second Amended Complaint (Clean)(2397290.1).docx	
Changes:	
<u>Add</u>	66
Delete	86
Move From	0
<u>Move To</u>	0
<u>Table Insert</u>	0
Table Delete	0
<u>Table moves to</u>	0
Table moves from	0
Embedded Graphics (Visio, ChemDraw, Images etc.)	0
Embedded Excel	0
Format changes	0
Total Changes:	152